Business Context and Reporting Period
This Form 8-K Current Report was filed by Krystal Biotech, Inc. on January 4, 2021. The report discloses corporate governance changes effective as of January 4, 2021, specifically the appointment of two new directors to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and associated compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the expansion of the Board of Directors:
- Dr. Jing Marantz appointed as a Class II director (term expires at the 2022 annual meeting).
- Dr. Christopher Mason appointed as a Class III director (term expires at the 2023 annual meeting).
- Both appointments were made by the Board on December 31, 2020, effective January 4, 2021.
Compensation and Governance Details
Under the Company's compensation policy for non-employee directors, the new appointees received the following:
- Initial Stock Options: Nonqualified stock options to purchase 13,600 shares each, with an exercise price equal to the closing price on the grant date. These vest in 36 equal monthly installments.
- Annual Retainer: $40,000 per year for each director.
- Annual Stock Options: Upon each subsequent annual stockholder meeting, each director is entitled to options for 6,800 shares, vesting in 12 equal monthly installments.
- Indemnification: Both directors entered into the Company's standard indemnification agreement.
Dr. Marantz brings experience from Acceleron Pharma, Alnylam Pharmaceuticals, Alexion Pharmaceuticals, and Biogen. Dr. Mason is the Founder and Chief Scientific Officer of AVROBIO, Inc., with extensive academic and biotech leadership experience in regenerative medicine.
Investor Verification Checklist
- Verify the closing stock price on January 4, 2021, to determine the exercise price of the initial 13,600 options granted to each new director.
- Review the Company's proxy statement or subsequent filings to confirm the directors' terms and voting class assignments (Class II vs. Class III).
- Monitor future 8-K filings or proxy statements for the annual grant of 6,800 additional options to these directors.
- Confirm that no undisclosed transactions involving the new directors exist under Item 404(a) of Regulation S-K, as stated in the filing.